Tamás Bíró
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tamás Bíró has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
László Kovács
Department of Physiology, Research Center for Molecular Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary
11 shared publications- Balázs István Tóth
University of Debrecen
10 shared publications Gabriella Czifra
Department of Physiology, Research Center for Molecular Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary
7 shared publicationsRalf Paus
Department of Dermatology, University Hospital Schleswig-Holstein, University of Lübeck, Lübeck 23538, Germany
5 shared publicationsAttila G. Szöllősi
3 shared publications- Attila Oláh
Department of Physiology, Faculty of Medicine University of Debrecen Debrecen Hungary
3 shared publications
Latest Publications
- 1 August 2011
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 131 (8) , 1605-1614
Activation of Transient Receptor Potential Vanilloid-3 Inhibits Human Hair Growth
- 1 August 2011
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 131 (8) , 1605-1614
Activation of Transient Receptor Potential Vanilloid-3 Inhibits Human Hair Growth
- 8 March 2011
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 461 (6) , 593-606
“Sebocytes’ makeup” - Novel mechanisms and concepts in the physiology of the human sebaceous glands
The pilosebaceous unit of the human skin consists of the hair follicle and the sebaceous gland. Within this “mini-organ”, the sebaceous gland has been neglected by the researchers of the field for several decades. Actually, it was labeled as a reminiscence of human development (“a living fossil with a past but no future”), and was thought to solely act as a producer of sebum, a lipid-enriched oily substance which protects our skin (and hence the body) against various insults. However, due to emerging research activities of the past two decades, it has now become evident that the sebaceous gland is not only a “passive” cutaneous “relic” to establish the physico-chemical barrier function of the skin against constant environmental challenges, but it rather functions as an “active” neuro-immuno-endocrine cutaneous organ. This review summarizes recent findings of sebaceous gland research by mainly focusing on newly discovered physiological functions, novel regulatory mechanisms, key events in the pathology of the gland, and future directions in both experimental and clinical dermatology.
- 8 March 2011
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 461 (6) , 593-606
“Sebocytes’ makeup” - Novel mechanisms and concepts in the physiology of the human sebaceous glands
The pilosebaceous unit of the human skin consists of the hair follicle and the sebaceous gland. Within this “mini-organ”, the sebaceous gland has been neglected by the researchers of the field for several decades. Actually, it was labeled as a reminiscence of human development (“a living fossil with a past but no future”), and was thought to solely act as a producer of sebum, a lipid-enriched oily substance which protects our skin (and hence the body) against various insults. However, due to emerging research activities of the past two decades, it has now become evident that the sebaceous gland is not only a “passive” cutaneous “relic” to establish the physico-chemical barrier function of the skin against constant environmental challenges, but it rather functions as an “active” neuro-immuno-endocrine cutaneous organ. This review summarizes recent findings of sebaceous gland research by mainly focusing on newly discovered physiological functions, novel regulatory mechanisms, key events in the pathology of the gland, and future directions in both experimental and clinical dermatology.
- Open Access
- 1 March 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (3) , 1474
Thyroid-Stimulating Hormone, a Novel, Locally Produced Modulator of Human Epidermal Functions, Is Regulated by Thyrotropin-Releasing Hormone and Thyroid Hormones
Several elements of the hypothalamic-pituitary-thyroid axis (HPT) reportedly are transcribed by human skin cell populations, and human hair follicles express functional receptors for TSH. Therefore, we asked whether the epidermis of normal human skin is yet another extrathyroidal target of TSH and whether epidermis even produces TSH. If so, we wanted to clarify whether intraepidermal TSH expression is regulated by TRH and/or thyroid hormones and whether TSH alters selected functions of normal human epidermis in situ. TSH and TSH receptor (TSH-R) expression were analyzed in the epidermis of normal human scalp skin by immunohistochemistry and PCR. In addition, full-thickness scalp skin was organ cultured and treated with TSH, TRH, or thyroid hormones, and the effect of TSH treatment on the expression of selected genes was measured by quantitative PCR and/or quantitative immunohistochemistry. Here we show that normal human epidermis expresses TSH at the mRNA and protein levels in situ and transcribes TSH-R. It also contains thyrostimulin transcripts. Intraepidermal TSH immunoreactivity is up-regulated by TRH and down-regulated by thyroid hormones. Although TSH-R immunoreactivity in situ could not be documented within the epidermis, but in the immediately adjacent dermis, TSH treatment of organ-cultured human skin strongly up-regulated epidermal expression of involucrin, loricrin, and keratins 5 and 14. Thus, normal human epidermis in situ is both an extrapituitary source (and possibly an indirect) target of TSH signaling, which regulates defined epidermal parameters. Intraepidermal TSH expression appears to be regulated by the classical endocrine controls that determine the systemic HPT axis.
- 1 March 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (3) , 1474
Open AccessThyroid-Stimulating Hormone, a Novel, Locally Produced Modulator of Human Epidermal Functions, Is Regulated by Thyrotropin-Releasing Hormone and Thyroid Hormones
Several elements of the hypothalamic-pituitary-thyroid axis (HPT) reportedly are transcribed by human skin cell populations, and human hair follicles express functional receptors for TSH. Therefore, we asked whether the epidermis of normal human skin is yet another extrathyroidal target of TSH and whether epidermis even produces TSH. If so, we wanted to clarify whether intraepidermal TSH expression is regulated by TRH and/or thyroid hormones and whether TSH alters selected functions of normal human epidermis in situ. TSH and TSH receptor (TSH-R) expression were analyzed in the epidermis of normal human scalp skin by immunohistochemistry and PCR. In addition, full-thickness scalp skin was organ cultured and treated with TSH, TRH, or thyroid hormones, and the effect of TSH treatment on the expression of selected genes was measured by quantitative PCR and/or quantitative immunohistochemistry. Here we show that normal human epidermis expresses TSH at the mRNA and protein levels in situ and transcribes TSH-R. It also contains thyrostimulin transcripts. Intraepidermal TSH immunoreactivity is up-regulated by TRH and down-regulated by thyroid hormones. Although TSH-R immunoreactivity in situ could not be documented within the epidermis, but in the immediately adjacent dermis, TSH treatment of organ-cultured human skin strongly up-regulated epidermal expression of involucrin, loricrin, and keratins 5 and 14. Thus, normal human epidermis in situ is both an extrapituitary source (and possibly an indirect) target of TSH signaling, which regulates defined epidermal parameters. Intraepidermal TSH expression appears to be regulated by the classical endocrine controls that determine the systemic HPT axis.
- 1 September 2009
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 129 (9) , 2096-2099
An “Ice-Cold” TR(i)P to Skin Biology: The Role of TRPA1 in Human Epidermal Keratinocytes
- 1 September 2009
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 129 (9) , 2096-2099
An “Ice-Cold” TR(i)P to Skin Biology: The Role of TRPA1 in Human Epidermal Keratinocytes
- 1 August 2009
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 30 (8) , 411-420
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities
- 1 August 2009
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 30 (8) , 411-420
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities
- 9 June 2009
- Published by Wiley in Oral Diseases
- Vol. 15 (5) , 328-335
Increased expression of TRPV1 in squamous cell carcinoma of the human tongue
Objectives: Recent reports have unambiguously identified the presence and the growth‐modulatory role of transient receptor potential vanilloid‐1 (TRPV1), a central integrator of pain sensation, on numerous non‐neuronal cell types and, of great importance, in certain malignancies. In this study, we have investigated the molecular expression of TRPV1 in the human tongue and its high‐incidence malignant (squamous cell carcinoma, SCC) and premalignant (leukoplakia) conditions.Methods: Immunohistochemistry, Western blotting and quantitative ‘real‐time’ Q‐PCR were performed to define the expression of TRPV1.Results: A weak and sparse TRPV1‐specific immunoreactivity was identified in the basal layers of the healthy human tongue epithelium. By contrast, we observed a dramatically elevated TRPV1‐immunoreactivity in all layers of the epithelium both in precancerous and malignant samples. Furthermore, statistical analysis revealed that the marked overexpression of TRPV1 found in all grades of SCC showed no correlation with the degree of malignancy of the tumours. Finally, the molecular expression of TRPV1 was also identified in an SCC‐derived cell line and was shown to be increased in parallel with the accelerated growth of the cells.Conclusion: Collectively, our findings identify TRPV1 as a novel, promising target molecule in the supportive treatment and diagnosis of human tongue SCC.
- 9 June 2009
- Published by Wiley in Oral Diseases
- Vol. 15 (5) , 328-335
Increased expression of TRPV1 in squamous cell carcinoma of the human tongue
Objectives: Recent reports have unambiguously identified the presence and the growth‐modulatory role of transient receptor potential vanilloid‐1 (TRPV1), a central integrator of pain sensation, on numerous non‐neuronal cell types and, of great importance, in certain malignancies. In this study, we have investigated the molecular expression of TRPV1 in the human tongue and its high‐incidence malignant (squamous cell carcinoma, SCC) and premalignant (leukoplakia) conditions.Methods: Immunohistochemistry, Western blotting and quantitative ‘real‐time’ Q‐PCR were performed to define the expression of TRPV1.Results: A weak and sparse TRPV1‐specific immunoreactivity was identified in the basal layers of the healthy human tongue epithelium. By contrast, we observed a dramatically elevated TRPV1‐immunoreactivity in all layers of the epithelium both in precancerous and malignant samples. Furthermore, statistical analysis revealed that the marked overexpression of TRPV1 found in all grades of SCC showed no correlation with the degree of malignancy of the tumours. Finally, the molecular expression of TRPV1 was also identified in an SCC‐derived cell line and was shown to be increased in parallel with the accelerated growth of the cells.Conclusion: Collectively, our findings identify TRPV1 as a novel, promising target molecule in the supportive treatment and diagnosis of human tongue SCC.
- Open Access
- 1 February 2009
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 129 (2) , 329-339
Transient Receptor Potential Vanilloid-1 Signaling as a Regulator of Human Sebocyte Biology
- 1 February 2009
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 129 (2) , 329-339
Open AccessTransient Receptor Potential Vanilloid-1 Signaling as a Regulator of Human Sebocyte Biology
- 12 January 2009
- Published by Wiley in Experimental Dermatology
- Vol. 18 (2) , 122-129
Protein kinase C isoenzymes differentially regulate the differentiation‐dependent expression of adhesion molecules in human epidermal keratinocytes
Abstract: Epidermal expression of adhesion molecules such as desmogleins (Dsg) and cadherins is strongly affected by the differentiation status of keratinocytes. We have previously shown that certain protein kinase C (PKC) isoforms differentially alter the growth and differentiation of human epidermal HaCaT keratinocytes. In this paper, using recombinant overexpression and RNA interference, we define the specific roles of the different PKC isoenzymes in modulation of expression of adhesion molecules in HaCaT keratinocytes. The level of Dsg1, a marker of differentiating keratinocytes, was antagonistically regulated by two Ca‐independent ‘novel’ nPKC isoforms; i.e. it increased by the differentiation‐promoting nPKCδ and decreased by the growth‐promoting nPKCε. The expression of Dsg3 (highly expressed in proliferating epidermal layers) was conversely regulated by these isoenzymes, and was also inhibited by the differentiation inducer Ca‐dependent ‘conventional’ cPKCα. Finally, the expression of P‐cadherin (a marker of proliferating keratinocytes) was regulated by all of the examined PKCs, also in an antagonistic manner (inhibited by cPKCα/nPKCδ and stimulated by cPKCβ/nPKCε). Collectively, the presented results strongly argue for the marked, differential, and in some instances antagonistic roles of individual Ca‐dependent and Ca‐independent PKC isoforms in the regulation of expression of adhesion molecules of desmosomes and adherent junctions in human epidermal keratinocytes.
- 12 January 2009
- Published by Wiley in Experimental Dermatology
- Vol. 18 (2) , 122-129
Protein kinase C isoenzymes differentially regulate the differentiation‐dependent expression of adhesion molecules in human epidermal keratinocytes
Abstract: Epidermal expression of adhesion molecules such as desmogleins (Dsg) and cadherins is strongly affected by the differentiation status of keratinocytes. We have previously shown that certain protein kinase C (PKC) isoforms differentially alter the growth and differentiation of human epidermal HaCaT keratinocytes. In this paper, using recombinant overexpression and RNA interference, we define the specific roles of the different PKC isoenzymes in modulation of expression of adhesion molecules in HaCaT keratinocytes. The level of Dsg1, a marker of differentiating keratinocytes, was antagonistically regulated by two Ca‐independent ‘novel’ nPKC isoforms; i.e. it increased by the differentiation‐promoting nPKCδ and decreased by the growth‐promoting nPKCε. The expression of Dsg3 (highly expressed in proliferating epidermal layers) was conversely regulated by these isoenzymes, and was also inhibited by the differentiation inducer Ca‐dependent ‘conventional’ cPKCα. Finally, the expression of P‐cadherin (a marker of proliferating keratinocytes) was regulated by all of the examined PKCs, also in an antagonistic manner (inhibited by cPKCα/nPKCδ and stimulated by cPKCβ/nPKCε). Collectively, the presented results strongly argue for the marked, differential, and in some instances antagonistic roles of individual Ca‐dependent and Ca‐independent PKC isoforms in the regulation of expression of adhesion molecules of desmosomes and adherent junctions in human epidermal keratinocytes.
- 1 October 2008
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 135 (4) , 507-514
Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma
Recently, functional cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) have been described in human prostate and prostate cancer-derived cell lines where the activation of the receptors resulted in inhibition of cellular growth. We, however, lack the description of the expression of these molecules in human prostate cancer (PCC) and in benign prostate hyperplasia (BPH). Therefore, immunohistochemistry, Western blotting, and quantitative “real-time Q-PCR were performed to define the expressions of CB1 and TRPV1 in healthy and diseased prostate tissues. CB1 was identified in epithelial and smooth muscle cells types of the human prostate, whereas TRPV1 was exclusively localized to the mucosal cells. We also found that the expression of CB1 and TRPV1 (both at the protein and mRNA levels) were significantly up-regulated in PCC. However, while the increased expression of TRPV1 showed a proper correlation with increasing PCC tumor grades, such phenomenon was not observed with CB1. In addition, we also measured markedly elevated CB1 levels in BPH tissues whilst the expression of TRPV1 was not altered when compared to healthy control prostate. Our findings strongly argue for that (1) the CB1 and TRPV1 molecules as well as their ligands may indeed possess a promising future role in the treatment of PCC; (2) TRPV1 may also serve as a prognostic factor in PCC; and (3) CB1 may act as a potential target molecule in the therapeutic management of BPH.
- 1 October 2008
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 135 (4) , 507-514
Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma
Recently, functional cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) have been described in human prostate and prostate cancer-derived cell lines where the activation of the receptors resulted in inhibition of cellular growth. We, however, lack the description of the expression of these molecules in human prostate cancer (PCC) and in benign prostate hyperplasia (BPH). Therefore, immunohistochemistry, Western blotting, and quantitative “real-time Q-PCR were performed to define the expressions of CB1 and TRPV1 in healthy and diseased prostate tissues. CB1 was identified in epithelial and smooth muscle cells types of the human prostate, whereas TRPV1 was exclusively localized to the mucosal cells. We also found that the expression of CB1 and TRPV1 (both at the protein and mRNA levels) were significantly up-regulated in PCC. However, while the increased expression of TRPV1 showed a proper correlation with increasing PCC tumor grades, such phenomenon was not observed with CB1. In addition, we also measured markedly elevated CB1 levels in BPH tissues whilst the expression of TRPV1 was not altered when compared to healthy control prostate. Our findings strongly argue for that (1) the CB1 and TRPV1 molecules as well as their ligands may indeed possess a promising future role in the treatment of PCC; (2) TRPV1 may also serve as a prognostic factor in PCC; and (3) CB1 may act as a potential target molecule in the therapeutic management of BPH.